- Home
- SRRK vs ALKT Comparison
SRRK vs ALKT Comparison
Compare SRRK & ALKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- ALKT
- Stock Information
- Founded
- SRRK 2012
- ALKT 2007
- Country
- SRRK United States
- ALKT United States
- Employees
- SRRK N/A
- ALKT N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- ALKT EDP Services
- Sector
- SRRK Health Care
- ALKT Technology
- Exchange
- SRRK Nasdaq
- ALKT Nasdaq
- Market Cap
- SRRK 2.8B
- ALKT 3.1B
- IPO Year
- SRRK 2018
- ALKT 2021
- Fundamental
- Price
- SRRK $26.49
- ALKT $35.93
- Analyst Decision
- SRRK Strong Buy
- ALKT Buy
- Analyst Count
- SRRK 7
- ALKT 9
- Target Price
- SRRK $34.00
- ALKT $38.00
- AVG Volume (30 Days)
- SRRK 984.5K
- ALKT 1.1M
- Earning Date
- SRRK 11-12-2024
- ALKT 10-30-2024
- Dividend Yield
- SRRK N/A
- ALKT N/A
- EPS Growth
- SRRK N/A
- ALKT N/A
- EPS
- SRRK N/A
- ALKT N/A
- Revenue
- SRRK N/A
- ALKT $315,562,000.00
- Revenue This Year
- SRRK N/A
- ALKT $28.58
- Revenue Next Year
- SRRK N/A
- ALKT $24.11
- P/E Ratio
- SRRK N/A
- ALKT N/A
- Revenue Growth
- SRRK N/A
- ALKT 26.73
- 52 Week Low
- SRRK $6.76
- ALKT $21.19
- 52 Week High
- SRRK $35.38
- ALKT $41.36
- Technical
- Relative Strength Index (RSI)
- SRRK 50.87
- ALKT 46.95
- Support Level
- SRRK $25.86
- ALKT $37.24
- Resistance Level
- SRRK $28.11
- ALKT $38.49
- Average True Range (ATR)
- SRRK 1.68
- ALKT 1.61
- MACD
- SRRK -0.92
- ALKT -0.39
- Stochastic Oscillator
- SRRK 11.71
- ALKT 25.62
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. Alkami Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency with the support of a proprietary, true cloud-based, multi-tenant architecture.